益生菌
精神分裂症(面向对象编程)
内科学
安慰剂
医学
动物双歧杆菌
鼠李糖乳杆菌
阳性与阴性症状量表
抗精神病药
肠易激综合征
胃肠病学
分裂情感障碍
随机对照试验
精神科
精神病
双歧杆菌
乳酸菌
生物
替代医学
细菌
病理
遗传学
作者
Faith Dickerson,Cassie R. Stallings,Andrea E. Origoni,Emily Katsafanas,Christina L. G. Savage,Lucy A. B. Schweinfurth,Joshana K. Goga,Sunil Khushalani,Robert H. Yolken
摘要
Article Abstract Objective: A range of immune system abnormalities have been associated with schizophrenia. Probiotic compounds modulate the immune response and offer a potential treatment strategy for schizophrenia. Probiotic compounds have also been observed to improve gastrointestinal dysfunction, which is a common problem in individuals with schizophrenia. We performed a randomized, double-blind, placebo-controlled trial to examine whether probiotic supplementation can reduce symptom severity in patients with schizophrenia receiving antipsychotic treatment and also whether probiotics are associated with bowel functioning. Methods: Outpatients with schizophrenia (N = 65) meeting DSM-IV criteria and with at least moderately severe psychotic symptoms were enrolled in the study from December 2010-August 2012. Following a 2-week placebo run-in period, patients were randomly assigned to 14 weeks of double-blind adjunctive probiotic (combined Lactobacillus rhamnosus strain GG and Bifidobacterium animalis subsp. lactis strain Bb12) or placebo therapy. Psychiatric symptoms were assessed biweekly with the Positive and Negative Syndrome Scale (PANSS), and patients were queried weekly about their gastrointestinal functioning. Results: Repeated-measures analysis of variance showed no significant differences in the PANSS total score between probiotic and placebo supplementation (F = 1.28, P = .25). However, patients in the probiotic group were less likely to develop severe bowel difficulty over the course of the trial (hazard ratio = 0.23; 95% CI, 0.09-0.61, P = .003). Conclusions: Probiotic supplementation may help prevent a common somatic symptom associated with schizophrenia. Trial Registration: ClinicalTrials.gov identifier: NCT01242371 Prim Care Companion CNS Disord 2014;16(1):doi:10.4088/PCC.13m01579 © Copyright 2014 Physicians Postgraduate Press, Inc. Submitted: September 6, 2013; accepted October 18, 2013. Published online: February 13, 2014. Corresponding author: Faith B. Dickerson, PhD, Stanley Research Program at Sheppard Pratt, Sheppard Pratt Health System, 6501 North Charles St, Baltimore, MD 21204 (fdickerson@sheppardpratt.org).
科研通智能强力驱动
Strongly Powered by AbleSci AI